Featured Study Opportunities
The Crohn's & Colitis Foundation utilizes Featured Study Opportunities to collaborate with academic and industry researchers to help enroll patients with Crohn’s disease and ulcerative colitis into clinical studies. The list below highlights our partners' current research studies. Please note that these partners have paid to have their trials posted below. Some partners' studies listed may be recipients of partial or full funding from the Crohn's & Colitis Foundation. This support does not imply recommendation or favor of the Foundation, as the Crohn's & Colitis Foundation does not endorse any particular study.
For a comprehensive listing of all research studies currently recruiting, please click here.
(For e.g NY instead of New York)
Current Results: 28 entries
The purpose of the study is to evaluate the safety and effectiveness of the study medicine in adults with ulcerative colitis.
Primary objective: To compare clinical efficacy by evaluating the clinical response to CBP-307 (P.O. for 12 consecutive weeks) versus placebo in subjects with moderate to severe UC
The purpose of the LATTICE-CD is to evaluate how well an oral investigational drug (called BMS- 986165) works and how safe it is for patients with moderately to severely active Crohn’s disease.
Full Study Title: A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo and Active-Controlled (Entyvio), Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of A Study Drug in Participants with Moderately to Severely Active Ulcerative Colitis [Expedition]
The primary objective of this study is to evaluate the efficacy and safety of a study drug versus placebo in patients with moderately to severely active Ulcerative Colitis.
Full Title Study: Pizzicato Study: A Phase 2A, double-blind, randomized, placebo-controlled, parallel group study to evaluate the efficacy and safety of oral PF-06651600 AND PF-06700841 as induction and open label extension treatment in patients with moderate to severe Crohn's disease
To evaluate the effectiveness of study drug PF 06651600 and study drug PF 06700841 compared to placebo (harmless pill) at Week 12 in participants with moderate to severe Crohn's Disease.
The purpose of this research study is to compare the effects of the study drugs, PF-06651600 and PF-06700841, with placebo to find out which is better for treating UC. PF-06651600 and PF-06700841 are investigational drugs.
The primary objectives of this study are to determine if an investigational drug called PF-06687234, is safe, tolerable, and effective as an add-on therapy to Infliximab in the treatment of patients with active ulcerative colitis.
The primary objective of this study is to test the hypothesis that treatment with LY3074828 is superior to placebo in inducing clinical remission at Week 12 in subjects with moderate to severe ulcerative colitis (UC). The secondary objectives are: -To evaluate the safety and tolerability of treatment with LY3074828. -To evaluate the efficacy of treatment with LY3074828 in inducing a clinical response at Week 12. -To evaluate endoscopic remission at Week 12 and Week 52. -To evaluate the effect of maintenance treatment with LY3074828 on the durability of clinical remission, endoscopic remission, and clinical response at Week 52. -To evaluate the effect of LY3074828 on health outcomes/quality of life measures. -To characterize the pharmacokinetic (PK) profile of LY3074828.
The Featured Study Opportunities page is made possible in part by: